THE STORY MAY BE BIG. THE EVIDENCE STILL HAS TO WEIGH IN.
Have you seen a medical headline, supplement, peptide, product, treatment, or longevity claim that sounds almost too remarkable to be true?
Send it to Founders.
From the Reader’s Net is where reader-submitted questions, advertisements, products, health claims, and clinical observations come ashore for a closer look. Dr. Wright and the Founders team trace the story back to its source, examine the available research, and explain what the evidence actually means—in language the public can understand.
What Can You Send Us?
- A screenshot or advertisement
- A social-media post or video
- A product you are considering
- A medical or longevity headline
- A scientific claim you want explained
- A clinical observation or question that deserves a careful answer
What Happens Next?
We identify the original claim or observation, locate the strongest available evidence, separate human research from laboratory and animal findings, and explain both what is known and what remains uncertain.
Some catches may be featured in Dr. Wright’s Stringer: The Founder’s Weekly Catch.
NEW FROM THE READER’S NET
Fibromyalgia: What We Know, What We Don’t—and What Comes Next
A reader living with fibromyalgia asked us to look deeper. We examine pain processing, genetics, the guaifenesin question, emerging research, and where patients can search for legitimate clinical trials.
FEATURED FROM THE READER’S NET
Can Exosomes Really Heal Every Major System in the Body?
CAUGHT IN DR. WRIGHT’S NET
Until our readers begin filling the net themselves, I will occasionally share advertisements, questions, and medical claims that have crossed my own screen—and answer the questions I believe patients should be asking.
The Claim
An advertisement from Apex Regenerative says exosomes work throughout the entire body. It credits them with reducing inflammation, repairing cells, growing a healthy blood supply, regenerating damaged tissue, and starting a healing cascade across the brain, nerves, heart, lungs, liver, kidneys, joints, muscles, and skin.
WHAT THE ADVERTISEMENT SAYS
- “Reduce inflammation” — “Calm the body”
- “Protect & repair cells” — “Help injured tissue recover”
- “Grow new, healthy blood supply” — “Bring oxygen & nutrients”
- “Regenerate damaged tissue” — including “nerves, joints, bone, muscle and more”
- “Start a healing cascade” — “Restore healthy function”
The advertisement concludes that exosomes can support healing in “every major system” and depicts the brain, nerves, heart, lungs, liver, kidneys, joints, muscles, and skin.
The missing information: Which exact exosome product produced each claimed benefit, in what dose and by what route, in which controlled human trials, and with what safety findings?
That leads to a fair question:
If exosomes are part of real science, does that mean an exosome treatment being sold today has been proven to heal the whole body?
The Short Answer
No.
Exosomes and other extracellular vesicles are real biological particles. They carry proteins, lipids, and genetic material between cells, and researchers are investigating them in inflammation, wound healing, tissue repair, drug delivery, cancer, neurologic disease, and many other fields.
But biological plausibility is not the same as clinical proof.
The existence of laboratory studies showing that a particular extracellular-vesicle preparation affects a particular cell, animal, or disease model does not prove that a commercial product will safely regenerate multiple organ systems in people.
What Are Exosomes?
Cells release tiny membrane-bound packages known as extracellular vesicles. Exosomes are one category within that broader family. These vesicles can carry signaling molecules from one cell to another and influence immune activity, blood-vessel growth, tissue remodeling, and other biological processes.
That communication system makes extracellular vesicles scientifically compelling. It also makes the word exosome sound like a single uniform medicine.
It is not.
An extracellular-vesicle product can differ according to:
- The cells from which it was produced
- The health and characteristics of the donor
- The conditions under which the cells were grown
- How the vesicles were isolated and purified
- The concentration, dose, and route of administration
- How the preparation was stored
- Its sterility, potency, identity, and contaminants
- Whether the final product actually contains what its label claims
Results from one carefully characterized research preparation cannot automatically be transferred to every product marketed as “exosomes.”
What the Research Actually Shows
Laboratory and animal studies provide evidence that some extracellular-vesicle preparations can alter inflammatory signaling, affect macrophage behavior, encourage angiogenesis, and support tissue repair in specific experimental settings.
Small early human studies and clinical trials are also exploring extracellular vesicles in selected conditions. That is legitimate and important research.
But the evidence is fragmented. Preparations, cell sources, purification methods, doses, routes, and outcomes vary substantially. Many studies remain preclinical; many human studies are small, early-phase, uncontrolled, or focused on narrow indications.
A study of umbilical-cord-derived vesicles in one disease model does not demonstrate simultaneous benefit to the brain, heart, lungs, kidneys, joints, nerves, muscles, liver, and skin. Nor does a paper about a biological mechanism validate a clinic’s particular vial.
Where the Advertisement Makes Its Leap
The advertisement takes several effects that extracellular vesicles may produce under some experimental conditions and presents them as though a treatment can reliably direct those effects throughout the human body.
That is the unsupported leap.
For a whole-body therapeutic claim to be convincing, we would need to know:
- The exact product being administered
- Its source, manufacturing method, and quality controls
- The dose and route of administration
- The specific condition being treated
- The clinical outcomes measured
- The number and characteristics of the patients studied
- The comparator or control group
- The duration of follow-up
- The adverse-event profile
- Whether independent investigators reproduced the result
A list of papers about different vesicles, tissues, and experimental models does not substitute for trials of the product being sold.
What Does the FDA Say?
The FDA states that exosome products intended to treat disease are regulated as drugs and biological products and require review before marketing. Its public safety notice says there are no FDA-approved exosome products and describes reports of serious adverse events involving unapproved products marketed as containing exosomes.
The agency advises patients considering an exosome treatment to ask whether it has been reviewed by the FDA. When a product is being studied under an Investigational New Drug application, patients can ask for the IND number and information about the responsible Institutional Review Board.
“Experimental” should mean studied under meaningful oversight—not simply sold with a consent form and a scientific-sounding explanation.
Questions to Ask Before Paying for an Exosome Treatment
- What is the exact product name and manufacturer?
- What human trial studied this exact product for my exact condition?
- Is there an FDA-approved indication or an active IND?
- What confirms identity, sterility, purity, potency, and dose?
- What adverse events have occurred?
- Who is responsible if I am harmed?
- Am I being asked to delay or replace an established treatment?
If the answers return repeatedly to animal studies, testimonials, before-and-after photographs, or research performed on a different preparation, the evidence has not caught up with the sale.
The Founder’s Verdict
Stringer Scale: Promising science; unproven commercial catch.
Exosomes are not imaginary, and extracellular-vesicle research should not be dismissed. They may eventually become useful therapeutic tools.
But this advertisement compresses an enormous, heterogeneous research field into a promise of systemic healing. The evidence does not currently establish that a commercial exosome product can safely reduce inflammation, repair cells, grow blood vessels, regenerate damaged tissue, and restore function across every major human organ system.
The science is real. The whole-body promise is not yet proven.
— Milton Wright, DO, FACOFP
Founding Director
Founders Institute of Medicine & Education
Sources: FDA Public Safety Notification on Exosome Products | Clinical Applications of Exosomes: A Critical Review (2024) | Systematic review of published clinical extracellular-vesicle studies | ClinicalTrials.gov: extracellular-vesicle infusion study
Educational information only. Not medical advice. This review evaluates public claims and does not determine the composition, sterility, or safety of any individual product.
ALSO FROM THE READER’S NET
FROM THE READER’S NET
A patient receiving modern cancer immunotherapy asks whether naturopathic care can remain part of her treatment plan.
Can Naturopathic Care and Immunotherapy Work Together?
Yes—if the operative word is together.
The Reader’s Question
A reader living with thyroid cancer reported that her tumor underwent genomic profiling and that she is now receiving pembrolizumab, better known as Keytruda. She also values naturopathic care and wants to know whether the two approaches can be combined.
Many people want the precision and disease-directed power of modern oncology while also seeking help with nutrition, sleep, stress, pain, fatigue, nausea, emotional health, and overall well-being.
The question should not be conventional medicine versus naturopathic medicine. The safer question is:
Can an oncology team and a complementary-care clinician build one coordinated plan in which every treatment has a defined purpose and nothing undermines the cancer therapy?
What Tumor Genomic Profiling Can Tell Us
Tumor biomarker testing—sometimes called molecular profiling, genomic testing, or next-generation sequencing—looks for biological features that may help physicians understand a cancer or select treatment.
Depending on the cancer, testing may identify gene alterations, protein expression, tumor mutational burden, microsatellite instability, mismatch-repair deficiency, or other findings relevant to an approved treatment or clinical trial.
Sequencing does not make every detected mutation actionable. Some findings guide therapy; others help with diagnosis or prognosis; still others have uncertain significance.
We do not know this reader’s tumor subtype, stage, biomarker result, or the precise reason Keytruda was chosen—and we should not guess. Those details belong with her oncology team.
What Keytruda Does
Pembrolizumab is an immune-checkpoint inhibitor. It blocks the PD-1 pathway, which some cancers use to reduce immune attack. Releasing that checkpoint can help the immune system recognize and attack tumor cells.
That is different from simply “boosting the immune system.” Immunotherapy changes immune regulation in a targeted but powerful way.
Because activated immunity can also injure healthy tissue, Keytruda can cause immune-mediated adverse reactions involving the lungs, colon, liver, kidneys, skin, thyroid, pituitary, adrenal glands, pancreas, nervous system, and other organs. New symptoms should not automatically be attributed to cancer, stress, diet, or a supplement.
Concerning symptoms—including new shortness of breath, persistent diarrhea, jaundice, severe rash, unusual weakness, marked headache or visual change, confusion, fever, or other significant changes—should be reported promptly to the oncology team.
Where Complementary Care May Help
Evidence-informed integrative oncology does not replace cancer treatment. Its purpose is to support the person receiving it.
- Nutrition assessment and treatment of deficiencies
- Physical activity adapted to strength and treatment tolerance
- Sleep and fatigue management
- Mindfulness, counseling, relaxation, or spiritual support
- Selected acupuncture, massage, acupressure, or other symptom-directed approaches when appropriate
- Pain, nausea, anxiety, and functional-support strategies
Professional oncology guidelines recognize selected integrative approaches for symptoms such as cancer-related pain, anxiety, and depression. The evidence is intervention-specific; “integrative” is not blanket validation of every complementary therapy.
Where the Risk Appears
The greatest danger is not that two clinicians have different training. It is that they operate from two separate medication lists and two separate treatment plans.
Herbs and supplements can affect drug metabolism, bleeding risk, liver or kidney function, immune signaling, and laboratory results. Product quality and dose may vary. With immune-checkpoint therapy, evidence for many supplements is particularly limited.
No supplement, restrictive diet, detoxification program, intravenous mixture, or alternative protocol should be assumed compatible with pembrolizumab merely because it is described as natural.
No complementary therapy should delay an infusion, replace oncology follow-up, or be used to manage a suspected immune-related adverse event without oncology involvement.
A Necessary Word About Homeopathy
Homeopathy and naturopathic medicine are not interchangeable.
Naturopathic practice can include nutrition, lifestyle counseling, botanical products, supplements, and other interventions—each of which must be judged individually for evidence and safety.
Homeopathy has not been shown to treat cancer or improve the cancer-controlling effect of Keytruda. Its greatest risk arises when it substitutes for effective treatment or delays evaluation. Products labeled homeopathic are also not always chemically inert; some contain measurable active ingredients.
What Genuine Coordination Looks Like
- Oncology directs cancer treatment. Keytruda dosing, monitoring, imaging, laboratory assessment, and management of immune toxicity remain with oncology.
- Complementary care has a defined supportive purpose. Each intervention targets a symptom, nutritional issue, or quality-of-life goal—not an unsupported promise to cure cancer.
- Everyone sees the same list. Every prescription, supplement, herb, tea, powder, injection, infusion, and dietary protocol is disclosed, including dose and brand.
- New products are reviewed before use. “Natural” does not establish compatibility.
- Symptoms are escalated promptly. Possible immune toxicity is not treated away without notifying oncology.
- Outcomes are measured. The team determines whether an intervention helps and whether harms appear.
The Founder’s Verdict
Coordinated Catch — Appropriate when oncology remains in the lead and supportive treatments are disclosed, evidence-informed, and monitored.
This patient does not necessarily have to choose between receiving sophisticated immunotherapy and being treated as a whole person. But she should never be asked to maintain two competing versions of her care.
The best model is a single transparent plan in which the oncologist, patient, and complementary-care clinician understand what is being used, why it is being used, what evidence supports it, and what could go wrong.
The goal is not to place two medical philosophies in the same room. It is to make them responsible to the same patient.
— Milton Wright, DO, FACOFP
Founding Director
Founders Institute of Medicine & Education
Sources: FDA prescribing information for Keytruda | National Cancer Institute: biomarker-directed therapies | NCI: cancer-therapy interactions with foods and supplements | NCI: diets, supplements, and cancer | Society for Integrative Oncology–ASCO guideline
This educational article is based on a de-identified reader question and is published with the reader’s consent. It does not identify her cancer subtype, biomarker result, stage, or treatment rationale and is not a substitute for her oncology team’s recommendations.
Have Something for the Net?
Send the link, screenshot, product name, clinical observation, or question through our contact page. Tell us what caught your attention and what you would like Founders to explain.
No hype. No ridicule. Just curiosity, context, and evidence.
Educational information only. Not medical advice. Submission does not guarantee publication or an individual response.